Pancreatic cancer
RAS(ON) inhibitors, pan-KRAS and the long wait for a second-line standard.
Registry changes (new trials, status, phase, endpoint and readout-date changes, results) come from the OncoSignal store, last verified against ClinicalTrials.gov 2026-11-11 08:25 UTC.
- New trialNew Ph1 trial: NCT07929961
National University Hospital, Singapore. Study of MC001 in Patients With Advanced Solid Tumours
- New trialNew Ph2 trial: NCT07920731
Fudan University. A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
- Results postedResults posted: NCT04753879
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
- Results postedResults posted: NCT03073785
Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer
- Results postedResults posted: NCT05111353
Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery
- PaperSitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial.
Yu J, Shi S, Li M et al. Signal transduction and targeted therapy.
- New trialNew Ph1 trial: NCT07909356
Medicovestor, Inc. A Study of MC001 in Patients With Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) and Other Folate Receptor Alpha (FRα)-Expressing Solid Tumors
- PaperImmunochemotherapy for Borderline Resectable or Locally Advanced Pancreatic Cancer: A Randomized Controlled Trial.
Bai X, Li X, Chen Y et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
- PaperOptimizing the Therapeutic Index: Sequential Intraarterial-Intravenous PRRT with Personalized Volumetric-Adjusted Dosing.
Bodei L, Ziv E, Mauguen A et al. Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
- Readout dueReadout due: NCT03816163 reached primary completion
Astellas Pharma Global Development, Inc.. A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
- New trialNew Ph1 trial: NCT07906691
Shanghai Hengrui Pharmaceutical Co., Ltd.. A Study to Assess the Effect of Itraconazole on the Pharmacokinetics of HRS-4642 Following Intravenous Infusion in Healthy Participants
- PaperKRAS in pancreatic cancer: from molecular biology to transformative therapeutics.
Abdelhakeem A, Ganatra N, Gul K et al. Journal of hematology & oncology.
- PaperPhase Ib-II study of ramucirumab combined with nab-paclitaxel and Gemcitabine as first-line treatment in patients with advanced pancreatic adenocarcinoma (RACING).
Papaxoinis G, Sgouros J, Korfiatis N et al. Cancer treatment and research communications.
- New trialNew Ph1/Ph2 trial: M-POP (NCT07905131)
Daniel Nussbaum, M.D.. A Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic Cancer
- New trialNew Ph3 trial: NCT07900789
Shanghai Hengrui Pharmaceutical Co., Ltd.. HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic Cancer
- PaperOptimizing first-line NALIRIFOX and exploring the role of the microbiota in second-line pancreatic cancer treatment: the PRODIGE 105-GERCOR 116 PANORAMIX trial.
Delaye M, Hilmi M, Gougis P et al. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
- Phase advanceERAS-0015 advances to Ph1/Ph2 (indication level)
Tango Therapeutics, Inc. posted NCT07897734: TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients
- New trialNew Ph1/Ph2 trial: NCT07897227
CSPC Megalith Biopharmaceutical Co.,Ltd.. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SYS6062 in Patients With Advanced Solid Tumors.
- New trialNew Ph1 trial: NCT07898683
National Medical Research Radiological Centre of the Ministry of Health of Russia. A Phase I Study of Intra-Arterial Yttrium-90 Radioembolization for Unresectable Pancreatic Cancer
- New trialNew Ph1 trial: NCT07898813
Dana-Farber Cancer Institute. Daraxonrasib in Resectable PDAC
- Results postedResults posted: NCT06015659
ZN-c3 + Gemcitabine in Pancreatic Cancer
- New trialNew Ph2 trial: NCT07895498
Memorial Sloan Kettering Cancer Center. A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer
- PaperLymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial.
George B, Singh H, Devoe CE et al. Nature medicine.
- PaperPerioperative chemotherapy and stereotactic body radiotherapy versus perioperative chemotherapy alone in patients with high-risk, localised pancreatic cancer (MASTERPLAN): an open-label, phase 2, multicentre, randomised trial of the Australasian Gastro-Intestinal Trials Group.
Oar A, Kneebone A, Sjoquist KM et al. The Lancet. Oncology.
- PaperClinical Outcomes of Gemcitabine Plus Nab-Paclitaxel-Based Chemoradiotherapy in a Multidisciplinary Treatment Strategy for Locally Advanced Pancreatic Cancer (NUPAT-05): A Prospective, Single-Arm, Phase II Study.
Yamada H, Tanaka H, Yamada S et al. International journal of cancer.
- PaperCarbon ion radiotherapy for non-metastatic pancreatic cancer: final results of the prospective phase 2 PACK-study (NCT04194268).
Liermann J, Naumann P, Jäkel C et al. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
- Results postedResults posted: NCT04141995
FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer
- PaperEfficacy and Safety of KRAS-Targeted Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: An Updated Systematic Review and Meta-Analysis of Pooled Proportions.
Fatima F, Javed MA, Mirza A et al. American journal of clinical oncology.
- PaperThe Evolution of Oligometastatic Pancreatic Ductal Adenocarcinoma: From Anatomic Description to Biologically Informed Patient Selection.
Gaur KS, Hall WA, Kamgar M et al. Cancers.
- New trialNew Ph1 trial: NCT07875920
Neowise Biotechnology. Phase 1 Study of NW-301V TCR-T Cells in Advanced Solid Tumors With KRAS G12V Mutation
- New trialNew Ph1 trial: NCT07875907
University of Florida. Repurposing Mefloquine for Pancreatic Cancer Treatment
- Results postedResults posted: NCT05512377
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
- New trialNew Ph2 trial: NCT07871461
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute). Utilizing Standard of Care Induction Chemotherapy Followed by MR-LINAC Radiotherapy and Surgical Exploration to Improve Resectability Rates in Potentially Resectable Locally Advanced Pancreatic Cancer
- PaperGlobal Landscape of Clinical Studies Open to Enrollment in Carbon Ion Radiotherapy: A PTCOG Review.
Holtzman AL, Giap H, Ishikawa H et al. International journal of particle therapy.
- Readout dueReadout due: NCT05945823 reached primary completion
Taiho Oncology, Inc.. Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
- PaperHeparin Wet Suction Versus Conventional Suction in Endoscopic Ultrasound-Guided Fine-Needle Biopsy for Solid Pancreatic Masses: A Multicenter Randomized Crossover Study.
Chon HK, Jang DK, Paik WH et al. Journal of gastroenterology and hepatology.
- Readout dueReadout due: NCT06412510 reached primary completion
Case Comprehensive Cancer Center. Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT
- PaperA phase II pilot evaluation of lurbinectedin in patients with advanced gastrointestinal malignancies with DNA repair mutations.
Viniotis AF, Jameson GS, Wertheim BC et al. Journal of gastrointestinal oncology.
- Readout dueReadout due: MRD-GI reached primary completion
Georgetown University. Evaluating Novel Therapies in ctDNA Positive GI Cancers
- Phase advanceTelisotuzumab Adizutecan advances to Ph2 (indication level)
AbbVie posted NCT07769502: A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers
- Readout dueReadout due: NCT04605913 reached primary completion
Mayo Clinic. Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
- Phase advanceRetifanlimab advances to Ph2 (indication level)
Massachusetts General Hospital posted EKLAVYA-HRD: Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC
- Phase advanceSintilimab advances to Ph2 (indication level)
Ruijin Hospital posted NCT07745790: Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer
- Phase advanceS-1 advances to Ph2 (indication level)
Ruijin Hospital posted NCT07745790: Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer
- Readout dueReadout due: NCT05632328 reached primary completion
Bruno Bockorny. AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC
- Readout dueReadout due: NCT04207944 reached primary completion
Duke University. The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)
- Readout dueReadout due: NCT05933265 reached primary completion
Lantern Pharma Inc.. Study of LP-184 in Patients With Advanced Solid Tumors
- Readout dueReadout due: PANCONVA reached primary completion
University of Kansas Medical Center. Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer
A phase advance is an asset's first trial at a higher phase than any earlier trial of the same asset in this indication. Readout due means the registry's primary completion date has passed; it is not a disclosure.